ATE234820T1 - Aminoalkyloxime, verfahren zur dessen herstellung,ihre verwendung als medikamente und zwischenprodukte - Google Patents

Aminoalkyloxime, verfahren zur dessen herstellung,ihre verwendung als medikamente und zwischenprodukte

Info

Publication number
ATE234820T1
ATE234820T1 AT95111895T AT95111895T ATE234820T1 AT E234820 T1 ATE234820 T1 AT E234820T1 AT 95111895 T AT95111895 T AT 95111895T AT 95111895 T AT95111895 T AT 95111895T AT E234820 T1 ATE234820 T1 AT E234820T1
Authority
AT
Austria
Prior art keywords
aminoalkyloximes
medications
production
intermediate products
aminoalkyloxines
Prior art date
Application number
AT95111895T
Other languages
English (en)
Inventor
Gregory Shutske
Brian S Freed
John Dick Tomer
R Richard L Hamer
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE234820T1 publication Critical patent/ATE234820T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
AT95111895T 1994-08-03 1995-07-28 Aminoalkyloxime, verfahren zur dessen herstellung,ihre verwendung als medikamente und zwischenprodukte ATE234820T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/285,668 US5665756A (en) 1994-08-03 1994-08-03 Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders

Publications (1)

Publication Number Publication Date
ATE234820T1 true ATE234820T1 (de) 2003-04-15

Family

ID=23095223

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95111895T ATE234820T1 (de) 1994-08-03 1995-07-28 Aminoalkyloxime, verfahren zur dessen herstellung,ihre verwendung als medikamente und zwischenprodukte

Country Status (9)

Country Link
US (8) US5665756A (de)
EP (1) EP0709378B1 (de)
JP (1) JP3947238B2 (de)
AT (1) ATE234820T1 (de)
CA (1) CA2155275C (de)
DE (1) DE69529958T2 (de)
DK (1) DK0709378T3 (de)
ES (1) ES2194033T3 (de)
PT (1) PT709378E (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60045751D1 (de) * 1999-09-30 2011-04-28 Harbor Biosciences Inc Therapeutische Behandlung androgenrezeptorbedingter Leiden
DE19952146A1 (de) * 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP2003531169A (ja) 2000-04-24 2003-10-21 アリックス セラピューティクス うつ病治療のための材料と方法
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
US8193768B2 (en) * 2008-02-28 2012-06-05 Jason S. Hallett Contactless charging system for musical instruments
US11498903B2 (en) 2017-08-17 2022-11-15 Bristol-Myers Squibb Company 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) * 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes
BE759128R (fr) * 1969-11-18 1971-05-18 Usv Pharma Corp Carbamoyl oximes et leur methode de
FR2162312B1 (de) * 1971-12-10 1975-02-07 Buzas Andre
FR2215953B2 (de) * 1973-02-05 1976-05-14 Buzas Andre
US4192893A (en) * 1975-03-20 1980-03-11 U.S. Philips Corporation Anti-depressive compounds
NL7503313A (en) * 1975-03-20 1976-09-22 Philips Nv Antiaggressive oxime ethers - viz 4-nitro-2-butyl(oxy)-acetophenone O-aminoalkyl-oximes
NL7503310A (nl) * 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
NL7610399A (en) * 1976-09-20 1978-03-22 Philips Nv O-Aminoethyl oxime derivs. of halophenyl ketone cpds. - are selective nor-adrenalin potentiators useful as antidepressants
GR61620B (en) * 1976-10-14 1978-12-04 Byk Gulden Lomberg Chem Fab Preparation process of pyrazol-1-yl-phenyloxic acids
DE2658762A1 (de) * 1976-12-24 1978-06-29 Hoechst Ag Neue o-alkylierte oxime, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE2658938A1 (de) * 1976-12-24 1978-07-06 Hoechst Ag Neue basisch substituierte 0-propyloxime, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4297359A (en) * 1978-07-25 1981-10-27 Acf Chemiefarma Nv Anti-ulcer compositions containing certain pyridyl oxime ethers
US4352804A (en) * 1978-07-25 1982-10-05 Acf Chemiefarma Nv Oxime ethers, their preparation and pharmaceutical compositions containing them
AU532700B2 (en) * 1979-04-02 1983-10-13 Sumitomo Chemical Company, Limited Diphenylalkanoether
DE3019497A1 (de) * 1980-05-22 1981-11-26 Bayer Ag, 5090 Leverkusen Aminopropiophenon-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
DE3070002D1 (en) * 1980-06-07 1985-03-07 Hell Rudolf Dr Ing Gmbh Process for operating a high stability electron gun for the shaping of materials
DE3169110D1 (en) * 1980-11-24 1985-03-28 Ici Plc Amide derivatives
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
JPS6463574A (en) * 1987-09-03 1989-03-09 Mitsubishi Chem Ind Ethanone oximes
GB8811056D0 (en) * 1988-05-10 1988-06-15 Ici Plc Antibiotic compounds
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
DE3927483A1 (de) * 1989-08-19 1991-02-21 Boehringer Ingelheim Kg Neue substituierte heterocyclische fuenfringe, ihre herstellung und verwendung
IL97144A (en) * 1990-02-27 1994-11-28 Erba Carlo Spa History of 1-) Alkoxy-Iminoalkyl (Imidazole Transformed Preparation and Pharmaceutical Preparations Containing Them

Also Published As

Publication number Publication date
EP0709378A2 (de) 1996-05-01
EP0709378B1 (de) 2003-03-19
DK0709378T3 (da) 2003-07-14
DE69529958D1 (de) 2003-04-24
PT709378E (pt) 2003-06-30
JP3947238B2 (ja) 2007-07-18
US5665756A (en) 1997-09-09
US5648367A (en) 1997-07-15
DE69529958T2 (de) 2004-01-08
US5684021A (en) 1997-11-04
EP0709378A3 (de) 1996-10-02
JPH0859617A (ja) 1996-03-05
US5686483A (en) 1997-11-11
US5686446A (en) 1997-11-11
CA2155275C (en) 2007-05-15
CA2155275A1 (en) 1996-02-04
US5686447A (en) 1997-11-11
ES2194033T3 (es) 2003-11-16
US5696142A (en) 1997-12-09
US5770740A (en) 1998-06-23

Similar Documents

Publication Publication Date Title
NO303574B1 (no) Ny fremgangsmÕte for fremstilling av 9-amino-6-demetyl-6-deoksytetracykliner
DE69532634D1 (de) Zwischenprodukte für die herstellung von pharmazeutischem camptothecin
ATE154003T1 (de) Verfahren zur herstellung von (e)-alkoximino- oder hydroxyiminoacetamidverbindungen und zwischenprodukte
ATE201025T1 (de) Verfahren zur herstellung von cephalosporinen und zwischenprodukte in diesem verfahren
ATE166355T1 (de) Substituierte aminothienopyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE234820T1 (de) Aminoalkyloxime, verfahren zur dessen herstellung,ihre verwendung als medikamente und zwischenprodukte
ATE299858T1 (de) Verfahren zur herstellung von diaminodiphenylmethan und seiner höheren homologen
ATE279424T1 (de) Neue verbindungen kf-1040 und verfahren zu ihrer herstellung
ATE277915T1 (de) Verfahren sowie neue zwischenprodukte zur herstellung von isoxazolin-3-yl-acylbenzolen
DE69517201D1 (de) Verfahren zur herstellung von 2-(2-hydroxymethylphenyl)acetamid-derivaten und zwischenprodukte zur herstellung
ATE385232T1 (de) Verfahren zur herstellung von 3, 3', 6, 6'- tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'- tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
ATE270287T1 (de) 2,3-dihydro-1h-isoindolderivate, verfahren zu ihrer herstellung und ihre verwendung als hemmer der serotoninwiederaufnahme
ATE152709T1 (de) Tetrahydrocyclopent(b>indole-methanamine und verwandte verbindungen, und verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE267832T1 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
ATE234288T1 (de) Verfahren zur herstellung eines buthylthuio- isochinolinderivates und zwischenprodukte dafür
DE69926223D1 (de) Verfahren zur herstellung von zwischenprodukten
ATE211136T1 (de) Coumarin-derivate, verfahren zu deren herstellung und deren verwendung
ATE216235T1 (de) Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie
DE69811893T2 (de) Verfahren zur herstellung von azetidin-2-carbonsäure und zwischenprodukten davon
ATE265421T1 (de) Verfahren zur herstellung von midodrin
ATE179417T1 (de) Glyceraldehyd-3-pentanid und verfahren zu ihrer herstellung
ATE191508T1 (de) Mikrobiologisches verfahren zur herstellung von 1-ungesättigten, 17-beta-carboxysubstituierten 3- oxo-4-azaandrostan-3-onen
DE69530229T2 (de) Verfahren zur herstellung von 1,5-pentandiol-derivaten
DE59610187D1 (de) Verfahren zur Herstellung von Härtevergleichsplatten
DE50007412D1 (de) Verfahren zur herstellung von n-substituierten 2,4-diamino-5-fluor-benzonitrilen und neue zwischenprodukte

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0709378

Country of ref document: EP

REN Ceased due to non-payment of the annual fee